Thrombotic events in severe FXII deficiency in comparison with unaffected family members during a long observation period.
Coagulation
Contact phase
FXII deficiency
Thrombosis
Journal
Journal of thrombosis and thrombolysis
ISSN: 1573-742X
Titre abrégé: J Thromb Thrombolysis
Pays: Netherlands
ID NLM: 9502018
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
pubmed:
30
1
2019
medline:
23
7
2019
entrez:
30
1
2019
Statut:
ppublish
Résumé
To investigate the occurrence of thrombotic events (myocardial infarction, deep vein thrombosis or ischemic stroke) in a group of 39 cases of severe FXII deficiency during a mean 22.5 years follow-up. All patients seen in Padua during the years 1968-2006 will the object of this investigation. FXII was less than or 1% of normal in all cases. Factor FXII activity in unaffected family members was 98% (range 90-140%). No patient or control had a thrombotic event in the past and none were on anticoagulant therapy. FV Leiden was present in one patient and in two controls whereas the G to A20210 prothrombin polymorphism was absent in both groups. There was one death among the patients (breast cancer) and one among the control (car accident). There were two thrombotic events (myocardial infarction and deep vein thrombosis) in the patient group and three (myocardial infarction and two deep vein thrombosis) in the control group. Heterozygous FV Leiden was present in the patient who had venous thrombosis, One of the two control subjects who developed venous thrombosis had heterozygous FV Leiden and was on oral contraception. The second control subject who developed venous thrombosis was on oral contraception and had varicose veins. No ischemic stroke was observed in the patients or controls. Periods of immobilization were 42 days and 38 days, respectively for FXII deficient patients and for the controls. Patients with severe FXII deficiency may present thrombotic events but these are similar to these presented by unaffected family members. As a consequence it may be stated that severe FXII deficiency does not appear to effect thrombotic events.
Identifiants
pubmed: 30694429
doi: 10.1007/s11239-019-01819-8
pii: 10.1007/s11239-019-01819-8
doi:
Types de publication
Comparative Study
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
481-485Références
Thromb Haemost. 1999 Oct;82(4):1240-6
pubmed: 10544906
J Thromb Thrombolysis. 2000 Apr;9(3):271-5
pubmed: 10728027
J Lab Clin Med. 1979 Aug;94(2):256-65
pubmed: 110893
Rev Med Interne. 2001 Feb;22(2):200-2
pubmed: 11234684
Thromb Res. 2002 May 15;106(4-5):265-7
pubmed: 12297136
Lancet. 1992 Jul 25;340(8813):237
pubmed: 1353152
J Clin Invest. 1955 Apr;34(4):602-13
pubmed: 14367514
J Thromb Thrombolysis. 2004 Apr;17(2):139-43
pubmed: 15306750
Clin Appl Thromb Hemost. 2005 Jan;11(1):49-53
pubmed: 15678272
Am J Ophthalmol. 2005 Mar;139(3):578-9; author reply 579-80
pubmed: 15767094
Clin Appl Thromb Hemost. 2005 Jul;11(3):335-8
pubmed: 16015420
Thromb Haemost. 1992 Feb 3;67(2):219-25
pubmed: 1621242
Blood Coagul Fibrinolysis. 2008 Oct;19(7):639-43
pubmed: 18832903
Thromb Haemost. 1991 Feb 12;65(2):117-21
pubmed: 1905067
J Thromb Thrombolysis. 2011 Jan;31(1):57-63
pubmed: 20577781
Expert Rev Hematol. 2010 Dec;3(6):685-95
pubmed: 21091145
Acta Haematol. 2016;136(2):118-22
pubmed: 27385629
Blood Coagul Fibrinolysis. 2018 Jul;29(5):423-428
pubmed: 29762144
Thromb Haemost. 1988 Aug 30;60(1):127
pubmed: 3187943
Clin Haematol. 1985 Jun;14(2):385-411
pubmed: 3899440
Arch Mal Coeur Vaiss. 1985 Mar;78(3):440-3
pubmed: 3923976
Br J Haematol. 1970 Aug;19(2):179-92
pubmed: 4989292
Riv Crit Clin Med. 1968;68(3):265-78
pubmed: 5737878
Medicine (Baltimore). 1983 Jul;62(4):248-55
pubmed: 6348471
Scand J Haematol. 1984 Jul;33(1):80-2
pubmed: 6463588
Acta Haematol. 1980;63(5):278-82
pubmed: 6774556
Br J Haematol. 1994 Jun;87(2):422-4
pubmed: 7947293
Nature. 1994 May 5;369(6475):64-7
pubmed: 8164741
Blood. 1996 Nov 15;88(10):3698-703
pubmed: 8916933